A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent

Part of paid clinical trials in Anaheim, California.

Sponsor
Mirati Therapeutics Inc.
Study ID
NCT07723118
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy Participants

Eligibility Criteria

Sex
ALL
Age
18 Years - 60 Years
Healthy Volunteers
Accepted

Interventions

  • Adagrasib — DRUG
    Specified dose on specified days

Study Details

The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent

Key Dates

First listed
Jul 23, 2026
Start date
Aug 5, 2026
Status verified
Aug 2026
Primary completion
Sep 8, 2026
Completion
Sep 12, 2026

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Adagrasib

Primary Outcome Measure

Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Up to Day 7 ]

Central Contacts

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
    855-907-3286
    [email protected]
  • First line of the email MUST contain NCT # and Site #.

Locations (1)

FacilityCityStateZIPSite coordinators
CenExel ACT (Formerly Anaheim Clinical Trials; LLC)AnaheimCalifornia92801
Peter Winkle, Site 0001

Find similar trials in Anaheim, CA

By research site
CenExel ACT (Formerly Anaheim Clinical Trials; LLC)· Anaheim, CA

Related Studies